Preventing Post–Organ Transplantation Cytomegalovirus Disease with Ganciclovir: A Meta‐Analysis Comparing Prophylactic and Preemptive Therapies
Open Access
- 1 October 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (7), 869-880
- https://doi.org/10.1086/507337
Abstract
Background. Cytomegalovirus (CMV) causes significant morbidity and mortality in transplant recipients, but there is no consensus regarding the most appropriate prevention method. The goal of this meta-analysis was to compare the efficacy of universal prophylaxis and preemption using ganciclovir. Methods. Literature searches for randomized and nonrandomized controlled trials of ganciclovir prophylaxis and preemption were conducted. Because of the lack of head-to-head trials, indirect comparisons of meta-analyses of the prevention strategies were performed. Meta-analyses were conducted using a random effects model to estimate the overall risk ratios for various clinical outcomes. We assessed the event rates for control groups across the trials for comparability. Results. Literature searches identified 17 universal prophylaxis trials and 9 preemption trials with 1560 and 457 subjects, respectively. Overall event rates for CMV disease in control groups across the studies were similar (∼26%). The relative risk of CMV disease in prophylaxis trials was 0.34 (95% confidence interval, 0.24–0.48) when trials of patients with prophylaxis of short duration and trials that only evaluated patients with high-risk serostatus were excluded. The relative risk of CMV disease for study subjects in all preemption trials was 0.30 (95% confidence interval, 0.15–0.60), compared with that for control subjects. There was no statistically significant difference in CMV disease between prevention strategies. Similarly, no differences between strategies were found for all-cause mortality or rejection. There were insufficient data to adequately evaluate graft loss and opportunistic infection. Conclusions. On the basis of indirect comparisons of meta-analyses of prevention strategies, universal prophylaxis and preemption are equally effective in reducing the incidence of CMV disease.Keywords
This publication has 48 references indexed in Scilit:
- Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation Final ReportAmerican Journal of Transplantation, 2005
- Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodiesTransplantation Proceedings, 2004
- Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejectionClinical Microbiology & Infection, 2004
- Preemptive Therapy Versus Universal Prophylaxis with Ganciclovir for Cytomegalovirus in Solid Organ Transplant RecipientsClinical Infectious Diseases, 2001
- Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipientsTransplantation Proceedings, 1999
- Clinical practice guidelinesJournal of the American Society of Nephrology, 1998
- Cytomegalovirus disease prophylaxis in renal transplantation by high dose oral acyclovir: efficacy and limitsTransplantation Proceedings, 1998
- GanciclovirDrugs, 1998
- Cytomegalovirus infection and disease after liver transplantationDigestive Diseases and Sciences, 1992
- Impact of Cytomegalovirus Infection on Organ Transplant RecipientsClinical Infectious Diseases, 1990